From: BCL-2 as therapeutic target for hematological malignancies
Disease(s) | Study phase | Estimated* or actual** enrollment | Register number in clinical trials.gov |
---|---|---|---|
NHL (non CLL/SLL/MCL) | I | 11** | NCT01969695 |
R/R CLL after BCRis (ibrutinib or idelalisib) | II | 127** | NCT02141282 |
R/R CLL/SLL and NHL | I | 211* | NCT01328626 |
R/R AML or untreated AML unfit for intensive therapy | II | 32** | NCT01994837 |
R/R or untreated CLL with 17p deletion | II | 158** | NCT01889186 |
R/R CLL | III | 250* | NCT02756611 |
R/R CLL with 17p deletion | II | 70* | NCT02966756 |
R/R CLL | III | 200* | NCT02980731 |
Waldenström Macroglobulinemia | II | 33** | NCT02677324 |